Literature DB >> 29687153

The use of broad-spectrum antibiotics reduces the incidence of surgical site infection after pancreatoduodenectomy.

Kimitaka Tanaka1, Toru Nakamura2, Shungo Imai3, Hiroki Kushiya1, Daisuke Miyasaka1, Yoshitsugu Nakanishi1, Toshimichi Asano1, Takehiro Noji1, Takahiro Tsuchikawa1, Keisuke Okamura1, Toshiaki Shichinohe1, Satoshi Hirano1.   

Abstract

PURPOSE: The development of surgical site infection (SSI) after biliary reconstruction is highly influenced by the presence of preoperative bacteria in the bile juice. We selected vancomycin and piperacillin/tazobactam (VCM + PIPC/TAZ) as perioperative prophylactic antibiotics for patients undergoing pancreaticoduodenectomy. This study aimed to retrospectively analyze the effectiveness of VCM + PIPC/TAZ compared to cefmetazole.
METHODS: Seventy-two patients who underwent pancreaticoduodenectomy between April 2015 and March 2017 at our department were evaluated. Forty patients were administered cefmetazole as the perioperative prophylactic antibiotic, and 32 were administered VCM + PIPC/TAZ. The intraoperative VCM blood concentration (incision, biliary reconstruction, and wound closure) was measured during surgery to confirm the hemodynamics.
RESULTS: The frequency of SSIs was significantly lower in the VCM + PIPC/TAZ group (8/32 patients) than in the cefmetazole group (20/40 patients, P = 0.031). Postoperatively, significantly fewer patients in the VCM + PIPC/TAZ group (4/32 patients) required ≥ 15 days of additional antibiotic administration compared to those in the cefmetazole group (14/40 patients, P = 0.033). Six of 32 patients in the VCM + PIPC/TAZ group showed redneck syndrome symptoms. There was no significant difference in the VCM blood concentration between patients with and without SSIs.
CONCLUSIONS: The use of VCM + PIPC/TAZ can reduce the incidence of SSI after pancreaticoduodenectomy and also reduce the need for the additional administration of antibiotics for ≥ 15 days after surgery.

Entities:  

Keywords:  Cefmetazole; Pancreaticoduodenectomy; Piperacillin/tazobactam; Surgical site infection; Vancomycin

Mesh:

Substances:

Year:  2018        PMID: 29687153     DOI: 10.1007/s00595-018-1658-3

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  41 in total

1.  Selection of prophylactic antibiotics according to the microorganisms isolated from surgical site infections (SSIs) in a previous series of surgeries reduces SSI incidence after pancreaticoduodenectomy.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Jiro Ohuchida; Masahiro Kai; Yoshiro Fujii; Kazuhiro Otani; Masahide Hiyoshi; Motoaki Nagano; Naoya Imamura
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-03       Impact factor: 7.027

Review 2.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After.

Authors:  Claudio Bassi; Giovanni Marchegiani; Christos Dervenis; Micheal Sarr; Mohammad Abu Hilal; Mustapha Adham; Peter Allen; Roland Andersson; Horacio J Asbun; Marc G Besselink; Kevin Conlon; Marco Del Chiaro; Massimo Falconi; Laureano Fernandez-Cruz; Carlos Fernandez-Del Castillo; Abe Fingerhut; Helmut Friess; Dirk J Gouma; Thilo Hackert; Jakob Izbicki; Keith D Lillemoe; John P Neoptolemos; Attila Olah; Richard Schulick; Shailesh V Shrikhande; Tadahiro Takada; Kyoichi Takaori; William Traverso; Charles R Vollmer; Christopher L Wolfgang; Charles J Yeo; Roberto Salvia; Marcus Buchler
Journal:  Surgery       Date:  2016-12-28       Impact factor: 3.982

3.  Impact of bacterial contamination of the abdominal cavity during pancreaticoduodenectomy on surgical-site infection.

Authors:  T Sugiura; T Mizuno; Y Okamura; T Ito; Y Yamamoto; I Kawamura; H Kurai; K Uesaka
Journal:  Br J Surg       Date:  2015-07-21       Impact factor: 6.939

4.  Current antibiotic prophylaxis in pancreatoduodenectomy in Japan.

Authors:  Tomio Ueno; Koutaro Yamamoto; Toru Kawaoka; Motonari Takashima; Masaaki Oka
Journal:  J Hepatobiliary Pancreat Surg       Date:  2005

5.  Perioperative complications following the use of vancomycin in children: a report of two cases.

Authors:  C J Best; M Ewart; E Sumner
Journal:  Br J Anaesth       Date:  1989-05       Impact factor: 9.166

6.  Risk factors for a high Comprehensive Complication Index score after major hepatectomy for biliary cancer: a study of 229 patients at a single institution.

Authors:  Yoshitsugu Nakanishi; Takahiro Tsuchikawa; Keisuke Okamura; Toru Nakamura; Eiji Tamoto; Takehiro Noji; Toshimichi Asano; Toraji Amano; Toshiaki Shichinohe; Satoshi Hirano
Journal:  HPB (Oxford)       Date:  2016-07-19       Impact factor: 3.647

7.  Randomized controlled trial of perioperative antimicrobial therapy based on the results of preoperative bile cultures in patients undergoing biliary reconstruction.

Authors:  Kunishige Okamura; Kimitaka Tanaka; Takumi Miura; Yoshitsugu Nakanishi; Takehiro Noji; Toru Nakamura; Takahiro Tsuchikawa; Keisuke Okamura; Toshiaki Shichinohe; Satoshi Hirano
Journal:  J Hepatobiliary Pancreat Sci       Date:  2017-05-06       Impact factor: 7.027

8.  Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

9.  The standard one gram dose of vancomycin is not adequate prophylaxis for MRSA.

Authors:  Anthony Catanzano; Michael Phillips; Yanina Dubrovskaya; Lorraine Hutzler; Joseph Bosco
Journal:  Iowa Orthop J       Date:  2014

10.  The effect of preoperative biliary stenting on postoperative complications after pancreaticoduodenectomy.

Authors:  Pamela Hodul; Steve Creech; Jack Pickleman; Gerard V Aranha
Journal:  Am J Surg       Date:  2003-11       Impact factor: 2.565

View more
  1 in total

Review 1.  Antibiotic Prophylaxis for Hepato-Biliopancreatic Surgery-A Systematic Review.

Authors:  Francesca Steccanella; Paolo Amoretti; Maria Rachele Barbieri; Fabio Bellomo; Alessandro Puzziello
Journal:  Antibiotics (Basel)       Date:  2022-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.